Novel Compounds for Male Contraception

Technology ID: 03KUMC300 

Description of Technology:  

Researchers at the University of Kansas Medical Center have begun investigating compounds which inhibit spermatogenesis by disrupting junctional complex sites between Sertoli cells and germ cells in the testes and developed novel compounds that demonstrate potent inhibition of spermatogenesis. These compounds are non-hormonal, non-hormonal, non steroidal, therefore eliminate some of the potential concerns for undesirable side effects. The same novel compounds are also found to be useful as inhibitors of heat shock 90 proteins (“Hsp90”) - the molecular chaperones responsible for protein folding and maturation in vivo and which have been found at higher levels in cancerous cells than in normal cells. The later property makes these compound also suitable target compounds for anti-cancer treatments. 

Filed of Applications: Male Contraception in humans and other mammals, Cancer Therapy

Advantages:   

• Currently, there is no oral contraception designed for males
• Non-hormonal, non-steroidal, thus few side-effects, 
• reversible,
• suitable for development of unique dosing regimen

Stage of Development: Animal data available

Industry Sectors:  Pharmaceutical Prescription

Therapeutic Targets: Contraception
                                      Oncology/Anti-Cancer

Patent Status: Patent Pending

Confidential Disclosure Agreement:  KUMC is willing to enter into a CDA for the purpose of negotiating a License Agreement.  If you are interested in learning details of this invention, please contact Technology Transfer at 913 588 5721.